CLINICAL TRIALS IN CIK THERAPY:
CURRENT AND UPCOMING STUDIES
A guide to the current clinical trial landscape for CIK cell therapy โ what is being studied, which combinations are advancing, and how international patients can access open trials at Chinese academic cancer centres.
analyticsAt a Glance
- check_circleActive CIK trials are testing combinations with PD-1 inhibitors, DC enhancement, and novel solid tumour indications
- check_circleChina's ChiCTR registry hosts the largest concentration of registered CIK trials globally
- check_circleInternational patients can participate in CIK clinical trials in China through CancerFax's trial identification service
- check_circleTrial participation may offer access to CIK protocols not available outside a research setting
The Current CIK Clinical Trial Landscape
CIK therapy's clinical trial activity has evolved over two phases: an earlier phase characterised by single-centre RCTs testing CIK alone or combined with chemotherapy across individual tumour types, and a current phase focused on novel combinations โ particularly with immune checkpoint inhibitors, DC enhancement, and in tumour types where CIK evidence has been limited. The majority of active trials are registered on China's ChiCTR (Chinese Clinical Trial Registry) and ClinicalTrials.gov.
โThe next frontier for CIK is not proving it works โ the RCT base has done that. It is understanding which combinations, which patients, and which biomarkers predict the strongest response.โ
CIK + PD-1/PD-L1 Inhibitor Combinations
The most clinically exciting area of current CIK trial activity. PD-1 inhibitor + CIK combinations are being tested in HCC, NSCLC, gastric cancer, and MSS colorectal cancer โ exploiting the biological complementarity between checkpoint disinhibition and adoptive cell infusion.
DC-CIK Optimisation Trials
Trials comparing standard CIK vs DC-CIK, investigating optimal antigen loading strategies, and evaluating DC-CIK in combination with chemotherapy and targeted agents are ongoing at multiple Chinese centres.
Novel Indications
CIK trials in pancreatic cancer, ovarian cancer, cervical cancer, triple-negative breast cancer, and rare sarcomas are exploring whether the broad-spectrum mechanism of CIK extends to tumour types with limited prior trial data.
Biomarker-Stratified CIK Trials
New generation trials are incorporating tumour biomarker stratification โ PD-L1 expression, TMB, MSI status, immune cell infiltration scores โ to identify which molecular features predict CIK response, enabling more precise patient selection.
Current CIK Trial Categories and Key Focus Areas
A structured overview of the main categories of CIK clinical trial activity currently registered on ChiCTR and ClinicalTrials.gov, organised by combination type and cancer focus.
| Trial Category | Cancer Types | Phase | Key Question Being Investigated |
|---|---|---|---|
| CIK + PD-1 inhibitor (sintilimab, camrelizumab) | HCC, NSCLC, gastric cancer | Phase I/II | Safety, ORR, and PFS of CIK + PD-1 vs either alone |
| CIK + anti-VEGF (bevacizumab, anlotinib) | NSCLC, CRC, HCC | Phase II | Whether VEGF blockade enhances CIK trafficking and efficacy |
| DC-CIK vs standard CIK (head-to-head) | HCC, NSCLC, gastric | Phase II/III | Whether DC co-culture significantly improves OS/PFS over CIK alone |
| CIK + TACE combination โ BCLC-B HCC | Intermediate-stage HCC | Phase III | Confirming OS benefit of CIK after TACE in larger prospective cohort |
| CIK in MSS colorectal cancer | MSS CRC (metastatic) | Phase II | ORR and PFS of CIK + FOLFOX in a population where IO fails |
| CIK in triple-negative breast cancer | TNBC (neoadjuvant/adjuvant) | Phase I/II | Feasibility and preliminary efficacy of CIK in TNBC treatment |
| Biomarker-selected CIK trials | Multiple solid tumours | Phase II | Whether TMB, PD-L1, or immune cell infiltration predicts CIK response |
| CIK in pancreatic cancer (adjuvant) | Resected pancreatic cancer | Phase II | DFS benefit of adjuvant CIK after pancreatic resection |
How International Patients Can Access CIK Clinical Trials in China
Enrolling in a clinical trial in China as an international patient requires navigating registration, eligibility screening, and logistics โ CancerFax manages this process on behalf of patients.
- 1
Record Submission and Clinical Assessment
Submit your medical records to CancerFax. Our clinical team assesses your cancer type, staging, biomarker profile, and prior treatment history โ the factors that determine eligibility for specific CIK trial protocols.
- 2
Trial Identification and Eligibility Matching
CancerFax searches active CIK trials on ChiCTR and ClinicalTrials.gov and at known active centres, identifying trials where your profile meets the published inclusion criteria and where international enrolment is permitted.
- 3
Principal Investigator Contact
We contact the trial's Principal Investigator or trial coordinator directly to confirm current enrolment status, international patient eligibility, and any protocol-specific requirements before you make any travel plans.
- 4
Remote Pre-Screening Consultation
Many Chinese trial teams conduct a remote pre-screening consultation (video call or document review) for international patients before formalising enrolment โ confirming fit before travel commitment.
- 5
Trial Enrolment, Visa, and Travel
Once pre-screening is passed, formal enrolment is initiated. CancerFax coordinates the medical visa invitation letter, travel arrangements, and hospital admission in alignment with the trial's screening visit schedule.
- 6
On-Trial Support and Follow-Up
CancerFax provides active support throughout the trial โ translating trial communications, coordinating between the trial team and your home oncologist, and managing logistics for subsequent trial visits.
Clinical Trial CIK vs Standard CIK Programme โ What to Consider
Enrolling in a clinical trial versus receiving CIK under a standard hospital programme involves different trade-offs โ patients should understand both before deciding.
Clinical Trial CIK
- Access to novel combinationsTrials provide access to CIK combinations (e.g. CIK + PD-1 inhibitor) that are not yet available as standard treatment โ potentially more active protocols.
- Highly structured clinical monitoringTrial protocols mandate regular safety and efficacy assessments โ providing more systematic clinical oversight than routine treatment.
- May involve reduced or no cost for trial therapyMany Chinese academic trials provide the investigational therapy at reduced or no cost to enrolled patients โ reducing total treatment expenditure.
- Contributing to scientific knowledgeTrial participation directly advances the evidence base for CIK therapy โ supporting its wider availability for future patients.
Standard Hospital CIK Programme
- Established protocols with known outcomesStandard CIK programmes use protocols backed by published RCT data โ patients know what response rates and safety profiles to expect.
- No randomisation riskIn randomised trials, the patient may be allocated to the control arm โ which may not include CIK therapy. Standard programmes guarantee the patient receives CIK.
- Broader eligibilityStandard CIK programmes typically have less restrictive eligibility criteria than clinical trials โ patients excluded from trials for protocol reasons may still receive standard CIK.
- Flexible schedulingStandard programmes can be more readily adapted to the patient's schedule and logistical constraints compared to rigid trial visit windows.
CIK Clinical Trial Activity โ Key Numbers
A quantitative snapshot of the current CIK clinical research landscape.
- 200+CIK-related studies registered on ChiCTR and ClinicalTrials.govThe Chinese Clinical Trial Registry hosts the world's largest concentration of CIK-related registered studies โ the majority at major academic cancer centres.
- CIK + PD-1Most active current combination trial categoryThe CIK + checkpoint inhibitor combination is the most intensively investigated new frontier in the current CIK trial landscape.
- 50+Countries from which CancerFax has supported patients accessing China cancer trialsCancerFax has established trial coordination pathways for patients across South Asia, the Middle East, Africa, Europe, and Southeast Asia.
Complete the CIK Therapy Resource Library
You have reached the final page of the CIK Resource Library. Explore the complete guide for everything you need to know about CIK therapy.
- CIK Cell Therapy โ Complete Treatment Guide
- The Evidence Base for CIK Therapy: What the Research Shows
- CIK Therapy vs Checkpoint Inhibitors: A Comparison
- How CancerFax Navigates CIK Therapy Access in China
- DC-CIK Combination Therapy: The Enhanced Immune Approach
- Patient Selection for CIK Therapy: Who Is a Good Candidate?
Frequently Asked Questions About CIK Clinical Trials
Can international patients enrol in CIK clinical trials in China?
Yes โ many CIK clinical trials at Chinese academic cancer centres accept international patients, subject to meeting eligibility criteria and logistical requirements. Chinese regulatory guidelines permit international trial enrolment at NMPA-supervised research sites. The key practical requirements are informed consent (with translation), the ability to attend required protocol visits in China, and meeting the trial's clinical inclusion and exclusion criteria. CancerFax confirms international enrolment status with the Principal Investigator before any patient makes travel commitments.
How do I find out what CIK trials are currently enrolling?
CancerFax searches both the Chinese Clinical Trial Registry (ChiCTR.org.cn) and ClinicalTrials.gov as part of our standard case review for patients seeking CIK therapy. We identify trials relevant to your specific cancer type, biomarker profile, and prior treatment history. You can also search ChiCTR directly using the search term 'CIK' or 'cytokine-induced killer', though navigating the Chinese-language registry and interpreting trial status accurately requires familiarity with the Chinese research system.
What is the difference between a Phase I, Phase II, and Phase III CIK trial?
Phase I trials primarily assess safety and tolerability โ they enrol small numbers of patients and are the earliest stage of investigation. Phase II trials evaluate preliminary efficacy (response rates, PFS) in a specific patient population โ providing evidence of activity and informing dose selection. Phase III trials are larger randomised studies designed to confirm efficacy and compare the new approach against the current standard of care โ the highest level of trial evidence. Most current CIK combination trials (e.g. CIK + PD-1 inhibitor) are Phase I/II; the adjuvant CIK in HCC literature includes Phase III data (Lancet Oncol 2015).
If I enrol in a trial, am I guaranteed to receive CIK therapy?
Not necessarily. Randomised trials allocate patients to arms by chance โ and the control arm may receive standard treatment without CIK. Before enrolling, CancerFax confirms with the trial team whether the trial is randomised, what the control arm receives, and what the probability is of CIK allocation. If you are not comfortable with randomisation risk, a standard CIK hospital programme (not a trial) provides certainty that you will receive CIK therapy. We present both options clearly before any enrolment decision is made.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If You Qualify for a CIK Clinical Trial?
CancerFax reviews your medical records and searches active CIK trials at Chinese academic centres for eligibility matches โ so you can access cutting-edge CIK protocols alongside or instead of standard treatment.
This content is for informational purposes only and does not constitute medical advice. Trial eligibility is determined by the trial's principal investigator, not by CancerFax. Always consult a qualified oncologist before enrolling in a clinical trial.